Total Payments
$1.1M
2024 Payments
$154,666
Companies
29
Transactions
842
Medicare Patients
589
Medicare Billing
$168,416
Payment Breakdown by Category
Other$697,666 (65.3%)
Consulting$256,299 (24.0%)
Travel$93,754 (8.8%)
Food & Beverage$17,269 (1.6%)
Research$3,838 (0.4%)
Education$13.93 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $640,132 | 216 | 59.9% |
| Consulting Fee | $256,299 | 94 | 24.0% |
| Travel and Lodging | $93,754 | 270 | 8.8% |
| Honoraria | $34,940 | 14 | 3.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $21,845 | 12 | 2.0% |
| Food and Beverage | $17,269 | 227 | 1.6% |
| Unspecified | $3,838 | 7 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $750.00 | 1 | 0.1% |
| Education | $13.93 | 1 | 0.0% |
Payments by Type
General
$1.1M
835 transactions
Research
$3,838
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $237,783 | 181 | $0 (2024) |
| Incyte Corporation | $141,121 | 102 | $0 (2024) |
| Kite Pharma, Inc. | $123,072 | 104 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $100,826 | 63 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $98,149 | 72 | $0 (2024) |
| ADC Therapeutics America, Inc. | $88,928 | 62 | $0 (2024) |
| GENZYME CORPORATION | $58,383 | 26 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $46,512 | 41 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $42,423 | 52 | $0 (2021) |
| SERVIER PHARMACEUTICALS LLC | $39,997 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $154,666 | 126 | E.R. Squibb & Sons, L.L.C. ($42,644) |
| 2023 | $196,296 | 143 | AstraZeneca Pharmaceuticals LP ($51,048) |
| 2022 | $154,608 | 107 | ADC Therapeutics America, Inc. ($33,467) |
| 2021 | $94,377 | 48 | Incyte Corporation ($26,210) |
| 2020 | $138,598 | 67 | Celgene Corporation ($56,927) |
| 2019 | $118,188 | 135 | Celgene Corporation ($35,616) |
| 2018 | $119,832 | 134 | Celgene Corporation ($57,813) |
| 2017 | $92,277 | 82 | Celgene Corporation ($60,666) |
All Payment Transactions
842 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,541.00 | General |
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,082.00 | General |
| 12/19/2024 | Incyte Corporation | NIKTIMVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $42.00 | General |
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,541.00 | General |
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,987.00 | General |
| 12/06/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $72.94 | General |
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $91.98 | General |
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $85.68 | General |
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $14.07 | General |
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $527.42 | General |
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $298.26 | General |
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $232.56 | General |
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $125.38 | General |
| 11/16/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | — | Cash or cash equivalent | $942.83 | Research |
| Study: CCTL019C2201,CCTL019B2202,CCTL019B2205J • Category: Oncology | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $644.51 | General |
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $254.24 | General |
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $575.15 | General |
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $119.32 | General |
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $775.19 | General |
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $599.98 | General |
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $508.77 | General |
| 11/12/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $215.74 | General |
| Category: Oncology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $119.51 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,580 | 3 |
| CCTL019C2201,CCTL019B2202,CCTL019B2205J | Novartis Pharmaceuticals Corporation | $942.83 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $315.78 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 109 | 287 | $122,174 | $28,266 |
| 2022 | 3 | 116 | 322 | $136,897 | $30,804 |
| 2021 | 4 | 160 | 420 | $183,441 | $43,780 |
| 2020 | 6 | 204 | 607 | $222,679 | $65,566 |
Total Patients
589
Total Services
1,636
Medicare Billing
$168,416
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 117 | $48,414 | $11,136 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 71 | $31,683 | $7,965 | 25.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 25 | 42 | $23,394 | $4,799 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 30 | $9,384 | $2,266 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 20 | 27 | $9,299 | $2,100 | 22.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 132 | $53,208 | $10,933 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 27 | 81 | $34,866 | $9,438 | 27.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 37 | 64 | $34,620 | $7,127 | 20.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 25 | $8,187 | $1,820 | 22.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 20 | $6,016 | $1,485 | 24.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 63 | 136 | $70,408 | $15,812 | 22.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 142 | $54,358 | $12,493 | 23.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 37 | 97 | $40,005 | $10,864 | 27.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $7,973 | $1,785 | 22.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 19 | $6,268 | $1,547 | 24.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 15 | $4,429 | $1,280 | 28.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 38 | 145 | $24,070 | $23,121 | 96.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 66 | 154 | $77,355 | $14,003 | 18.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 145 | $54,295 | $13,012 | 24.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 36 | 108 | $43,276 | $10,053 | 23.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 11 | 11 | $7,615 | $1,605 | 21.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $6,672 | $1,575 | 23.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 16 | $4,716 | $1,106 | 23.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 17 | $4,680 | $1,090 | 23.3% |
About Michael Bishop
Michael Bishop is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2011. The National Provider Identifier (NPI) number assigned to this provider is 1558666214.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Bishop has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $154,666 received in 2024. These payments were reported across 842 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($640,132).
As a Medicare-enrolled provider, Bishop has provided services to 589 Medicare beneficiaries, totaling 1,636 services with total Medicare billing of $168,416. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 01/11/2011
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1558666214
Products in Payments
- Revlimid (Drug) $142,649
- JAKAFI (Drug) $136,131
- CALQUENCE (Drug) $100,826
- Yescarta (Drug) $96,894
- REBLOZYL (Biological) $63,384
- TIBSOVO (Drug) $55,956
- ONUREG (Drug) $32,972
- Epkinly (Drug) $29,221
- ELITEK (Biological) $26,088
- KYMRIAH (Biological) $23,374
- Tibsovo (Drug) $21,056
- ELITEK (Drug) $17,559
- Pomalyst (Drug) $17,486
- Tecartus (Drug) $14,529
- SARCLISA (Biological) $8,255
- Zydelig (Drug) $6,964
- EPKINLY (Drug) $6,939
- Imbruvica (Drug) $6,684
- Amtagvi (Drug) $4,373
- JCAR017 (Drug) $3,475
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678
Randy Sweis
Hematology & Oncology — Payments: $346,946
Hematology & Oncology $346,946